Form 4: Emergent BioSolutions CFO Reports Stock Option Grant, Tax Withholding
Insider Transaction Report
Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, reported the acquisition of 72,856 employee stock options and the disposition of 23,650 common shares for tax purposes.
Summary
- Richard S. Lindahl, Executive Vice President and Chief Financial Officer of Emergent BioSolutions Inc. (EBS), reported recent transactions.
- On March 3, 2026, Lindahl acquired 72,856 employee stock options with an exercise price of $8.99 per share.
- These options are scheduled to vest in three equal annual installments, beginning on March 2, 2027, and will expire on March 2, 2033.
- On March 5, 2026, Lindahl disposed of 23,650 shares of common stock at a price of $8.44 per share.
- This disposition represents shares withheld to cover taxes associated with the vesting and settlement of restricted stock units.
- Following these transactions, Lindahl beneficially owns 215,367 shares of common stock and 557,346 derivative securities (employee stock options).
Sentiment
Score: 6
Explanation: StockSavvy.ai views this filing as slightly positive. While there was a disposition of shares, it was for tax purposes, and the significant grant of new stock options indicates continued executive alignment with future company performance.
Positives
- The acquisition of 72,856 employee stock options aligns the CFO's interests with long-term shareholder value creation.
- The options have a seven-year expiration period, providing a substantial window for potential value realization.
Negatives
- The disposition of 23,650 common shares, while for tax purposes, reduces the direct beneficial ownership of the CFO.
Industry Context
StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures of executive compensation and share plan management. The grant of stock options is a common incentive mechanism in the biotechnology and pharmaceutical industry to align executive performance with shareholder returns.
Stakeholder Impact
- Shareholders: The grant of stock options to the CFO aligns management's incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
- Employees: The compensation structure for executives, including stock options, can influence overall company morale and retention strategies.
Next Steps
- The employee stock options will vest in three equal installments beginning on March 2, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/03/2026 | Date of earliest transaction (acquisition of employee stock options). |
| 03/05/2026 | Transaction date for common stock disposition (tax withholding) and signature date of the filing. |
| 03/02/2027 | First vesting date for the acquired employee stock options. |
| 03/02/2028 | Second vesting date for the acquired employee stock options. |
| 03/02/2029 | Third and final vesting date for the acquired employee stock options. |
| 03/02/2033 | Expiration date of the employee stock options. |
Recommendation
holdThis Form 4 details routine insider transactions related to executive compensation. While the option grant is a positive for executive alignment, the filing does not contain sufficient new fundamental information to warrant a change in investment recommendation. Investors should consider broader company performance and market conditions.
Keywords
Emergent BioSolutions, EBS, Richard S. Lindahl, CFO, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.